Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma

Urology

Volumn 47, Issue 4, 1996, Pages 525-528

  Froschermaier, Stefan E ^a   Pilarsky, Christian P ^a   Wirth, Manfred P ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CALCULATION; DATA ANALYSIS; DIFFERENTIAL DIAGNOSIS; ENZYME INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

AGED; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0029997813     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80488-9     Document Type: Article

References (24)

1. Wirth MP, Manseck A, and Heimbach D: Value of prostate-specific antigen as a tumor marker. Eur Urol 24 (suppl 2): 6-12, 1993.
2. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA, and Lilja H: Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
3. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, and Chu TM: A prostate antigen in sera of prostatic cancer patients. Cancer Res 40: 2428-2432, 1980.
4. Partin AW, and Oesterling JE: The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358-1368, 1994.
5. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, and Redwine E: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
6. Brawer MK, and Lange PH: Prostate-specific antigen in management of prostatic carcinoma. Urology 33 (suppl 5): 1-16, 1989.
7. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, and Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
8. Hudson MA, Bahnson RR, and Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142: 1011-1017, 1989.
9. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, and Emond J: Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 147: 846-852, 1992.
10. Smith DS, and Catalona WJ: The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152: 1732-1736, 1994.
11. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
12. Babaian RJ, Dinney CP, Ramirez EI, and Evans RB: Diagnostic testing for prostate cancer detection: less is best. Urology 41: 421-425, 1993.
13. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, and Southwick PC: Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 152: 2031-2036, 1994.
14. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, and Southwick PC: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
15. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, and Cooner WH: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147: 815-816, 1992.
16. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, Chan DW, Fozard JL, and Walsh PC: Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostate disease. Cancer Res 52: 3323-3328, 1992.
17. Catalona WJ, Smith DS, and Ratliff TL: Value of measurements of the rate of change of serum PSA levels in prostate cancer screening. J Urol 149: 300A, 1993.
18. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
19. Brawer MK, Aramburu EA, Chen GL, Preston SD, and Ellis WJ: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 150: 369-373, 1993.
20. Lilja H, Cockett AT, and Abrahamsson PA: Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum. Cancer 70: 230-234, 1992.
21. Stenman UH, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, and Alfthan O: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
22. Wood WG, van der Sloot E, and Bohle A: The establishment and evaluation of luminescent-labelled immunometric assays for prostate-specific antigen alpha-1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 29: 787-794, 1991.
23. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220 1995.
24. Prestigiacomo A, Stamey T, Lilja H, Pettersson K, and Wolfert B: Comparison of patients with benign prostatic hyperplasia (BPH) and prostate cancer (CaP) by measuring non-complexed "free" prostate specific antigen (PSA): The "best case" scenario. J Urol 153: 462A, 1995.